Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy

Oral tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor (EGFR) family have been introduced into the clinic to treat human malignancies for decades. Despite superior properties of EGFR-TKIs as small molecule targeted drugs, their applications are still restricted due to their...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaohan, Shi, Kun, Hao, Ying, Yang, Chengli, Zha, Ruoyu, Yi, Cheng, Qian, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shenyang Pharmaceutical University 2020
Materias:
Review article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066044/
https://www.ncbi.nlm.nih.gov/pubmed/32175016
http://dx.doi.org/10.1016/j.ajps.2019.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066044/
https://www.ncbi.nlm.nih.gov/pubmed/32175016
http://dx.doi.org/10.1016/j.ajps.2019.06.001

Ejemplares similares